Identifying patients with multidrug-resistant tuberculosis who may benefit from shorter durations of treatment.

Journal:

PloS one, Volume: 18, Issue: 10

Published:

October 5, 2023

PMID:

37797071

Authors:

Nicholas Winters N, Mireille E Schnitzer ME, Jonathon R Campbell JR, Susannah Ripley S, Carla Winston C, Rada Savic R, Nafees Ahmad N, Gregory Bisson G, Keertan Dheda K, Ali Esmail A, Medea Gegia M, Ignacio Monedero I, Margareth Pretti Dalcolmo MP, Denise Rodrigues D, Rupak Singla R, Jae-Joon Yim JJ, Dick Menzies D

Access Paper

DOI: 10.1371/journal.pone.0292106

PMID: 37797071

Abstract:

Studying treatment duration for rifampicin-resistant and multidrug-resistant tuberculosis (MDR/RR-TB) using observational data is methodologically challenging. We aim to present a hypothesis generating approach to identify factors associated with shorter duration of treatment.

Courtesy of the U.S. National Library of Medicine